Negro Roberto, Greco Gabriele, Žarković Miloš
Department of Experimental Medicine. University of Salento, Lecce, Italy.
Division of Endocrinology. V. Fazzi Hospital, Lecce, Italy.
Endocrine. 2025 Jun 11. doi: 10.1007/s12020-025-04307-7.
To evaluate the outcomes of symptomatic nonfunctioning benign thyroid nodules treated with laser ablation (LA) over a 10-year follow-up.
This retrospective study included patients treated with LA between January 2010 and December 2014 and followed for 10 years. The patient's nodule volume was recorded at baseline, after 6 months, and then annually from the date of the LA procedure. We assessed the volume reduction ratio (VRR), technique efficacy, regrowth rate, additional treatments (surgery or LA), and complications.
One hundred nine patients were included in the study cohort. The 1-year VRR was 56.3%; technique efficacy was detected in 76 of 109 patients (69.7%). Sixty-nine out of 109 (63.3%) patients did not require a second treatment (LA or surgery) and these 69/109 (63.3%) patients showed a stable VRR of 65%. Regrowth was observed in 28 of 109 (25.7%) patients. EU-TIRADS 2 category, intranodular vascularity, and delivered energy ≥500 J/mL prevented technique inefficacy, regrowth, and retreatment (LA or surgery). Transient complications occurred in 3 out of 109 (2.7%) patients.
In this 10-year follow-up study, benign thyroid nodules submitted to LA experienced a stable VRR of 65% in more than 60% of patients. To maximize VRR and technique efficacy, LA should be particularly used in EU-TIRADS 2 nodules with intranodular vascularity that should preferably receive ≥ 500 J/mL of energy.
评估经激光消融(LA)治疗的有症状的无功能良性甲状腺结节在10年随访期内的治疗效果。
这项回顾性研究纳入了2010年1月至2014年12月期间接受LA治疗并随访10年的患者。在基线、6个月后以及自LA手术之日起每年记录患者结节体积。我们评估了体积缩小率(VRR)、技术疗效、再生长率、额外治疗(手术或LA)以及并发症。
研究队列纳入了109例患者。1年VRR为56.3%;109例患者中有76例(69.7%)检测到技术疗效。109例患者中有69例(63.3%)不需要二次治疗(LA或手术),这69/109(63.3%)例患者的VRR稳定在65%。109例患者中有28例(25.7%)观察到结节再生长。EU-TIRADS 2类、结节内血管形成以及输送能量≥500 J/mL可防止技术无效、结节再生长以及再次治疗(LA或手术)。109例患者中有3例(2.7%)发生了短暂并发症。
在这项10年随访研究中,接受LA治疗的良性甲状腺结节在超过60%的患者中VRR稳定在65%。为了使VRR和技术疗效最大化,LA应特别用于具有结节内血管形成的EU-TIRADS 2类结节,这类结节最好接受≥500 J/mL的能量。